iRhythm Technologies (IRTC) Competitors

$114.66 -3.65 (-3.09%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$114.68 +0.02 (+0.01%)

As of 05/13/2026 07:44 PM Eastern

IRTC vs. ZBH, SNN, PEN, SOLV, and GKOS

Should you buy iRhythm Technologies stock or one of its competitors? MarketBeat compares iRhythm Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iRhythm Technologies include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Penumbra (PEN), Solventum (SOLV), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does iRhythm Technologies compare to Zimmer Biomet?

iRhythm Technologies (NASDAQ:IRTC) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

iRhythm Technologies currently has a consensus target price of $193.38, indicating a potential upside of 68.66%. Zimmer Biomet has a consensus target price of $102.80, indicating a potential upside of 24.35%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe iRhythm Technologies is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has a net margin of 9.05% compared to iRhythm Technologies' net margin of -3.53%. Zimmer Biomet's return on equity of 13.24% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Zimmer Biomet	9.05%	13.24%	7.28%

In the previous week, Zimmer Biomet had 5 more articles in the media than iRhythm Technologies. MarketBeat recorded 10 mentions for Zimmer Biomet and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.81 beat Zimmer Biomet's score of 0.85 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zimmer Biomet	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Zimmer Biomet has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.04	-$44.55M	-$0.86	N/A
Zimmer Biomet	$8.23B	1.94	$705.20M	$3.85	21.47

88.9% of Zimmer Biomet shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Zimmer Biomet beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

How does iRhythm Technologies compare to Smith & Nephew SNATS?

iRhythm Technologies (NASDAQ:IRTC) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Smith & Nephew SNATS has a net margin of 0.00% compared to iRhythm Technologies' net margin of -3.53%. Smith & Nephew SNATS's return on equity of 0.00% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Smith & Nephew SNATS	N/A	N/A	N/A

iRhythm Technologies presently has a consensus target price of $193.38, indicating a potential upside of 68.66%. Smith & Nephew SNATS has a consensus target price of $30.93, indicating a potential upside of 3.65%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe iRhythm Technologies is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40

Smith & Nephew SNATS has higher revenue and earnings than iRhythm Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.04	-$44.55M	-$0.86	N/A
Smith & Nephew SNATS	$6.16B	2.07	$625M	N/A	N/A

In the previous week, iRhythm Technologies had 3 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 5 mentions for iRhythm Technologies and 2 mentions for Smith & Nephew SNATS. iRhythm Technologies' average media sentiment score of 1.81 beat Smith & Nephew SNATS's score of 0.23 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Smith & Nephew SNATS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Summary

iRhythm Technologies beats Smith & Nephew SNATS on 8 of the 15 factors compared between the two stocks.

How does iRhythm Technologies compare to Penumbra?

Penumbra (NYSE:PEN) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Penumbra presently has a consensus target price of $361.33, suggesting a potential upside of 12.05%. iRhythm Technologies has a consensus target price of $193.38, suggesting a potential upside of 68.66%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

88.9% of Penumbra shares are held by institutional investors. 2.9% of Penumbra shares are held by insiders. Comparatively, 1.0% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Penumbra has a net margin of 11.76% compared to iRhythm Technologies' net margin of -3.53%. Penumbra's return on equity of 10.87% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

In the previous week, Penumbra had 3 more articles in the media than iRhythm Technologies. MarketBeat recorded 8 mentions for Penumbra and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.81 beat Penumbra's score of 0.03 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Penumbra	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Penumbra has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Penumbra has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	9.04	$177.69M	$4.34	74.30
iRhythm Technologies	$747.14M	5.04	-$44.55M	-$0.86	N/A

Summary

Penumbra beats iRhythm Technologies on 11 of the 17 factors compared between the two stocks.

How does iRhythm Technologies compare to Solventum?

Solventum (NYSE:SOLV) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Solventum has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Solventum has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.55	$1.56B	$8.16	9.12
iRhythm Technologies	$747.14M	5.04	-$44.55M	-$0.86	N/A

Solventum has a net margin of 17.33% compared to iRhythm Technologies' net margin of -3.53%. Solventum's return on equity of 23.51% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

In the previous week, Solventum had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 6 mentions for Solventum and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.81 beat Solventum's score of 0.30 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Solventum presently has a consensus price target of $85.91, indicating a potential upside of 15.42%. iRhythm Technologies has a consensus price target of $193.38, indicating a potential upside of 68.66%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts clearly believe iRhythm Technologies is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.46
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

Summary

Solventum beats iRhythm Technologies on 8 of the 15 factors compared between the two stocks.

How does iRhythm Technologies compare to Glaukos?

iRhythm Technologies (NASDAQ:IRTC) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

99.0% of Glaukos shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 5.8% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, iRhythm Technologies had 1 more articles in the media than Glaukos. MarketBeat recorded 5 mentions for iRhythm Technologies and 4 mentions for Glaukos. iRhythm Technologies' average media sentiment score of 1.81 beat Glaukos' score of 0.85 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

iRhythm Technologies presently has a consensus price target of $193.38, indicating a potential upside of 68.66%. Glaukos has a consensus price target of $144.42, indicating a potential upside of 5.27%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe iRhythm Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

iRhythm Technologies has a net margin of -3.53% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Glaukos	-34.34%	-6.92%	-5.25%

iRhythm Technologies has higher revenue and earnings than Glaukos. iRhythm Technologies is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.04	-$44.55M	-$0.86	N/A
Glaukos	$507.44M	15.88	-$187.69M	-$3.28	N/A

Summary

iRhythm Technologies beats Glaukos on 11 of the 16 factors compared between the two stocks.

Get iRhythm Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRTC vs. The Competition

Export

Metric	iRhythm Technologies	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.89B	$1.44B	$6.30B	$12.20B
Dividend Yield	N/A	N/A	2.79%	5.30%
P/E Ratio	-133.32	64.77	20.99	25.65
Price / Sales	5.04	6.14	555.98	78.93
Price / Cash	N/A	23.25	42.94	55.34
Price / Book	23.35	5.19	9.70	6.66
Net Income	-$44.55M	-$54.76M	$3.55B	$333.63M
7 Day Performance	-8.18%	-2.67%	-0.56%	-0.11%
1 Month Performance	-6.95%	5.65%	1.17%	3.94%
1 Year Performance	-18.37%	-4.88%	41.20%	36.07%

iRhythm Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRTC iRhythm Technologies	4.4204 of 5 stars	$114.66 -3.1%	$193.38 +68.7%	-18.0%	$3.89B	$747.14M	N/A	2,400	Positive News
ZBH Zimmer Biomet	4.5394 of 5 stars	$82.24 -1.4%	$102.80 +25.0%	-15.1%	$16.13B	$8.23B	21.36	17,000
SNN Smith & Nephew SNATS	2.5601 of 5 stars	$29.90 -0.5%	$34.75 +16.2%	+5.6%	$12.83B	$6.16B	N/A	16,988	Analyst Forecast
PEN Penumbra	3.3802 of 5 stars	$322.15 -0.8%	$361.33 +12.2%	+9.1%	$12.77B	$1.40B	74.23	4,700
SOLV Solventum	3.2315 of 5 stars	$73.30 +2.3%	$85.91 +17.2%	+0.9%	$12.41B	$8.33B	8.98	20,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRTC) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRhythm Technologies (IRTC) Competitors

IRTC vs. ZBH, SNN, PEN, SOLV, and GKOS

How does iRhythm Technologies compare to Zimmer Biomet?

Summary

How does iRhythm Technologies compare to Smith & Nephew SNATS?

Summary

How does iRhythm Technologies compare to Penumbra?

Summary

How does iRhythm Technologies compare to Solventum?

Summary

How does iRhythm Technologies compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRTC vs. The Competition

iRhythm Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRhythm Technologies (IRTC) Competitors

IRTC vs. ZBH, SNN, PEN, SOLV, and GKOS

How does iRhythm Technologies compare to Zimmer Biomet?

Do analysts prefer IRTC or ZBH?

Is IRTC or ZBH more profitable?

Does the media refer more to IRTC or ZBH?

Which has more risk and volatility, IRTC or ZBH?

Which has stronger earnings & valuation, IRTC or ZBH?

Do insiders and institutionals believe in IRTC or ZBH?

Summary

How does iRhythm Technologies compare to Smith & Nephew SNATS?

Is IRTC or SNN more profitable?

Do analysts prefer IRTC or SNN?

Which has stronger earnings and valuation, IRTC or SNN?

Does the media favor IRTC or SNN?

Do institutionals & insiders have more ownership in IRTC or SNN?

Which has more risk & volatility, IRTC or SNN?

Summary

How does iRhythm Technologies compare to Penumbra?

Do analysts rate PEN or IRTC?

Do insiders and institutionals hold more shares of PEN or IRTC?

Is PEN or IRTC more profitable?

Does the media refer more to PEN or IRTC?

Which has more risk and volatility, PEN or IRTC?

Which has better earnings and valuation, PEN or IRTC?

Summary

How does iRhythm Technologies compare to Solventum?

Which has more volatility and risk, SOLV or IRTC?

Which has higher earnings and valuation, SOLV or IRTC?

Is SOLV or IRTC more profitable?

Does the media favor SOLV or IRTC?

Do analysts prefer SOLV or IRTC?

Summary

How does iRhythm Technologies compare to Glaukos?

Do institutionals and insiders believe in IRTC or GKOS?

Does the media refer more to IRTC or GKOS?

Which has more volatility and risk, IRTC or GKOS?

Do analysts prefer IRTC or GKOS?

Is IRTC or GKOS more profitable?

Which has preferable earnings & valuation, IRTC or GKOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRTC vs. The Competition

iRhythm Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools